Personal Genome Diagnostics, Inc. announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with Blueprint Medicines Corp. PGDx is an innovator in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, and Blueprint Medicines is an expert in developing highly selective kinase inhibitors for a genetically defined patient population. PGDx leverages the deep expertise of its scientific founders, who are internationally recognized leaders in cancer genomics at Johns Hopkins University, and its proprietary technologies to provide advanced genome-mapping services and analyses to oncology researchers, drug developers and clinicians. The founders of PGDx were the first to analyze the entire set of kinase genes in tumors, the "kinome", and have identified alterations in a variety of protein and lipid kinases, including the discovery of alterations in PIK3CA, one of the most frequently mutated genes in human cancer. PGDx has also been a pioneer in enabling scientists and clinicians to comprehensively analyze entire exomes and genomes to identify novel cancer alterations. As part of the collaboration, PGDx will employ a number of technologies including cancer exome analysis to capture and selectively analyze tumor sequences. These approaches, when combined with other patented PGDx technologies and computational methods, enable comprehensive analysis and unbiased detection of novel cancer-related mutations.

Personal Genome Diagnostics, Inc. is moving to a new, larger office to accommodate the two-year-old company's growth. The company will be moving from the Johns Hopkins Science and Technology Park to a 9,000-square-foot space at the Tindeco Wharf building on Boston Street in Canton.